Does long-term continuous administration of pentoxifylline affect platelet function in the critically ill patient?

Area of Science:

• Pharmacology
• Critical Care Medicine
• Hematology

Background:

• Pentoxifylline (PTX) is investigated for its anti-inflammatory and anti-aggregation properties.
• The long-term effects of PTX on platelet function in critically ill patients remain unclear.

Purpose of the Study:

• To evaluate the effects of continuous pentoxifylline infusion on platelet function in trauma and sepsis patients.
• To determine if PTX influences platelet aggregation and fibrinogen levels in critically ill patients.

Main Methods:

• Prospective, randomized study involving 52 patients (26 trauma, 26 sepsis) in a surgical intensive care unit.
• Patients received either pentoxifylline (1.5 mg/kg/h for 5 days) or placebo.
• Platelet aggregation (ADP, collagen, epinephrine) and coagulation parameters were measured over 5 days.

Main Results:

• Platelet aggregation decreased in untreated trauma and sepsis patients but recovered over time.
• PTX treatment resulted in significantly less impairment of platelet aggregation in sepsis patients and increased aggregation in trauma patients.
• Fibrinogen plasma levels were lower in control groups compared to PTX groups.

Conclusions:

• Continuous pentoxifylline infusion for 5 days did not impair platelet function in critically ill patients.
• PTX attenuated the expected deterioration of platelet function in trauma and sepsis.
• Observed benefits may relate to PTX's effects on cytokine release, microcirculation, or fibrinolysis.